Share on LinkedInShare on LinkedIn

ARTICLE · 11 NOVEMBER 2020

Intrinsic Evidence Trumps

Finnegan, Henderson, Farabow, Garrett & Dunner LLP
Finnegan, Henderson, Farabow, Garrett & Dunner LLP
Contributor
Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Finnegan, Henderson, Farabow, Garrett & Dunner LLP is one of the world’s largest firms focusing on...

View firm profile
Explore more from Finnegan, Henderson, Farabow, Garrett & Dunner LLP

In Immunex Corp. v. Sanofi-Aventis U.S. LLC, No. 2019-1749 (Fed. Cir. Oct. 13, 2020), the U.S. Court of Appeals for the Federal Circuit affirmed the Patent Trial and Appeal Board's decision in an inter partes review.

United StatesIntellectual Property

Holding: In Immunex Corp. v. Sanofi-Aventis U.S. LLC, No. 2019-1749 (Fed. Cir. Oct. 13, 2020), the U.S. Court of Appeals for the Federal Circuit ("Federal Circuit") affirmed the Patent Trial and Appeal Board's ("Board") decision in an inter partes review ("IPR") IPR2017-01884 that all of the claims of U.S. Patent No. 8,678,487 ("the '487 patent") were unpatentable. Id. at Slip Op. page 2. Sanofi-Aventis U.S. LLC., Genzyme Corp. and Regeneron Pharmaceuticals. Inc. (collectively, "Sanofi") filed the IPR petition challenging the '487 patent claims owned by Immunex Corp. ("Immunex"). Id.

Background: Sanofi filed three IPRs, and the Board instituted two of them as IPR2017-01884 and IPR2017-01879. Id. at 5. In IPR2017-01884, the Board found all challenged claims unpatentable, but in the other instituted IPR (IPR2017-01879), the Board did not, for reasons of inventorship. Id. at 2. Immunex appealed the unpatentability decision, and Sanofi appealed the inventorship

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from